Taking advantage of anti-inflammation property of EVs derived from regulatory T cells (Treg-EVs) and the ability of VEGF antibody in suppressing VEGF activity, Tian et al. engineered Treg-EVs via conjugating VEGF antibodies to the surface of Treg-EVs to strengthen the repair outcome in choroidal neovascularization (CNV)[63]. The gene discussed is VEGFA; the disease is choroidal neovascularization.